694 related articles for article (PubMed ID: 18404164)
21. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
22. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.
Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
J Surg Res; 2008 May; 146(1):43-8. PubMed ID: 17631905
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
24. Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.
Campreciós G; Lorita J; Pardina E; Peinado-Onsurbe J; Soley M; Ramírez I
J Cell Physiol; 2011 Feb; 226(2):450-5. PubMed ID: 20672328
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.
Sithanandam G; Fornwald LW; Fields J; Anderson LM
Oncogene; 2005 Mar; 24(11):1847-59. PubMed ID: 15688028
[TBL] [Abstract][Full Text] [Related]
26. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
[TBL] [Abstract][Full Text] [Related]
27. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
28. The role of ErbB3 binding protein 1 in cancer: Friend or foe?
Nguyen DQ; Hoang DH; Nguyen Vo TT; Huynh V; Ghoda L; Marcucci G; Nguyen LXT
J Cell Physiol; 2018 Dec; 233(12):9110-9120. PubMed ID: 30076717
[TBL] [Abstract][Full Text] [Related]
29. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
[TBL] [Abstract][Full Text] [Related]
30. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels.
Diamonti AJ; Guy PM; Ivanof C; Wong K; Sweeney C; Carraway KL
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2866-71. PubMed ID: 11867753
[TBL] [Abstract][Full Text] [Related]
31. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
32. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
33. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.
Knowlden JM; Gee JM; Barrow D; Robertson JF; Ellis IO; Nicholson RI; Hutcheson IR
Breast Cancer Res; 2011 Sep; 13(5):R93. PubMed ID: 21939528
[TBL] [Abstract][Full Text] [Related]
34. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
35. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
Samant GV; Sylvester PW
Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
[TBL] [Abstract][Full Text] [Related]
36. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
37. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
38. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
39. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Ciardiello C; Roca MS; Noto A; Bruzzese F; Moccia T; Vitagliano C; Di Gennaro E; Ciliberto G; Roscilli G; Aurisicchio L; Marra E; Mancini R; Budillon A; Leone A
Oncotarget; 2016 Apr; 7(15):19559-74. PubMed ID: 26862736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
